题名

免疫生物製劑於氣喘重症之應用

DOI

10.6647/CN.201812_25(4).0004

作者

郭夙吟；楊水河

关键词
期刊名称

彰化護理

卷期/出版年月

25卷4期（2018 / 12 / 01）

页次

7 - 10

内容语文

繁體中文
主题分类 醫藥衛生 > 預防保健與衛生學
醫藥衛生 > 社會醫學
参考文献
  1. Omalizumab (2018) ．藥品仿單喜瑞樂®注射劑．取自https://www.fda.gov.tw/MLMS/ShowFile.aspx?LicId=60001062&Seq=001&Type=9
  2. Mepolizumab (2018)．藥品仿單舒肺樂®凍晶注射劑．取自http://tw.gsk.com/media/716369/nucala-pi.pdf
  3. Bel, E. H.,Wenzel, S. E.,Thompson, P. J.,Prazma, C. M.,Keene, O. N.,Yancey, S. W.,Pavord, I. D.(2014).Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma.New England journal of medicine,371(13),1189-1197.
  4. Bleecker, E. R.,FitzGerald, J. M.,Chanez, P.,Papi, A.,Weinstein, S. F.,Barker, P.,Goldman, M.(2016).Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial.The Lancet,388(10056),2115-2127.
  5. FitzGerald, J. M.,Bleecker, E. R.,Nair, P.,Korn, S.,Ohta, K.,Lommatzsch, M.,Gilmartin, G.(2016).Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial.The Lancet,388(10056),2128-2141.
  6. Hanania, N. A.,Wenzel, S.,Rosén, K.,Hsieh, H. J.,Mosesova, S.,Choy, D. F.,Busse, W.(2013).Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study.American journal of respiratory and critical care medicine,187(8),804-811.
  7. NICE(2017).Asthma: diagnosis, monitoring and chronic asthma management.
  8. Normansell, R.,Walker, S.,Milan, S.J.,Walters, E.H.,Nair, P.(2014).Omalizumab for asthma in adults and children.Cochrane Database Syst Rev,13(1),CD003559.
  9. Pavord, I. D.,Korn, S.,Howarth, P.,Bleecker, E. R.,Buhl, R.,Keene, O. N.,Chanez, P.(2012).Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial.The Lancet,380(9842),651-659.
  10. 王瑩(2017)。Mepolizumab在嗜酸性白血球表現型的嚴重氣喘治療。台灣氣喘衛教學會會刊，44，3-8。
  11. 台灣氣喘諮詢協會(2017).台灣氣喘診療指引.台灣氣喘診療指.
  12. 林慶雄(2013)。嚴重氣喘病人的標靶治療。台灣氣喘衛教學會會刊，33，4-5。
print cancel